GlaxoSmithKline has exited the CDS platform operator, which has been purchased by patient care software provider Amalgam Rx for an undisclosed sum.

Echo Health Ventures has joined Arkansas Blue Cross Blue Shield's investment arm in a strategic initiative aimed at scaling up healthcare businesses.

The Sinopharm and WuXi AppTec-backed, complement system-focused drug developer has hauled in $53.3m of new funding after emerging from stealth late last year.

The cardiovascular treatment device developer raised about $46m in a round led by Tencent and has now secured roughly $60m altogether.

The transistor technology developer has disclosed $21.8m in series A funding from investors including Agilent Technologies across three tranches.

Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.

Genomic drug developer Tessera Therapeutics raised $230m in a round co-led by SoftBank Vision Fund 2 as it works on its gene writing technology.

Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.

LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.

Lilly Asia Ventures has led a $23.2m round for the digital diagnostics technology developer, investing alongside new and existing backers.